TriSalus Life Sciences, Inc. (TLSI) company profile
Close on Nov 18, 2026Market cap $150.86MP/E –Yield –
About TriSalus Life Sciences
Surgical & Medical Instruments & Apparatus, SIC 3841
TriSalus Life Sciences, Inc. is an oncology-focused medical technology company that develops drug delivery systems and investigational therapeutics for treating solid tumors. Its primary commercial product is the TriNav Infusion System, which utilizes Pressure-Enabled Drug Delivery technology and SmartValve mechanisms to overcome high intratumoral pressure during interventional embolization procedures. The business operates across delivery device technology and investigational immunotherapy segments, including development of nelitolimod and the Pancreatic Retrograde Venous Infusion system. Its direct customers comprise hospital value analysis committees, interventional radiologists, medical oncologists, and related clinical support personnel.
The enterprise markets its proprietary devices across the United States through a dedicated commercial network of 43 sales and marketing professionals. Its delivery technology has been deployed in more than 31,000 clinical procedures across multiple participating hospitals, ambulatory surgery centers, and academic medical institutions. TriSalus Life Sciences is incorporated under the laws of Delaware, with the provided report text containing no specific details regarding its corporate headquarters.
Summary of the business section of TriSalus Life Sciences's latest annual report, written by StockData.
Company profile
Company
- Legal name
- TriSalus Life Sciences, Inc.
- Headquarters
- Westminster, CO
- Address
- 6272 West 91st Avenue 80031
- Phone
- (415) 336-8917
- Website
- trisaluslifesci.com
- Employees
- 102, Dec 31, 2025
- Industry
- Surgical & Medical Instruments & Apparatus
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- Grant Thornton LLP, Chicago, Illinois
Stock & identifiers
- Ticker
- TLSI
- Other tickers
- TLSIW
- Former tickers
- MTAC until Aug 16, 2023
- Exchange
- Nasdaq
- IPO date
- Dec 21, 2020
- Shares outstanding
- 62M, Aug 4, 2026
- Public float
- $111.50M, Jun 30, 2025
- Filer category
- Non-accelerated filer<br>Smaller reporting company
- SEC CIK
- 1826667
- CUSIP
- 89680M101
- ISIN
- US89680M1018
- FIGI
- BBG00Z1TKRG8
- Share class FIGI
- BBG00Z1TKRH7
- EIN
- 85-3009869
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Mary T. Szela | CEO and President, Director | 1,074,990 |
| Richard Marshak | Chief Commercial Officer | 127,450 |
| Jennifer Stevens | Chief Regulatory Officer | 123,794 |
| Bryan F. Cox | Chief of Research | 162,805 |
| David Patience | Chief Financial Officer | 261,107 |
| Richard Henry Marshall | Chief Medical Officer | 30,000 |
| Jodi Devlin | Chief of Clinical Operations | 97,364 |
| James Emmett Young | Chief Financial Officer | 79,663 |
| Mats Wahlstrom | Director | 3,012,030 |
| Gary B. Gordon | Director | 72,510 |
| Michael P. Stansky | Director | 1,640,420 |
| William Valle | Director | 83,241 |
| Kerry R. Hicks | Director | 2,317,400 |
| David J. Matlin | Director | 1,300,145 |
| Sean Murphy | Director | 679,256 |
| Arjun JJ Desai | Director | 247,127 |
| Liselotte Hyveled | Director | 10,040 |
CEO pay and shareholder return
Pay versus performance table from the proxy statement
| Fiscal year | CEO total pay | CEO pay actually paid | Other executives (avg) | Value of $100 invested | Peer group |
|---|---|---|---|---|---|
| FY2025 | $4.82M | $6.89M | $2.50M | $83 | – |
| FY2024 | $4.14M | $1.52M | $1.85M | $59 | – |
“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.
Executive compensation, fiscal 2025
Summary compensation table from the latest proxy statement
| Executive | Salary | Bonus | Stock awards | Option awards | Other | Total | vs. prior year |
|---|---|---|---|---|---|---|---|
| Mary Szela CEO and President | $600.92K | $153.12K | $2.57M | $1.48M | $15.80K | $4.82M | +17% |
| David Patience Chief Financial Officer(*) | $268.46K | $239.19K | $1.14M | $1.72M | $77.68K | $3.44M | – |
| Richard Marshak Chief Commercial Officer | $435.33K | $113.54K | $399.25K | $592.28K | $15.61K | $1.56M | +14% |
Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.
IPO
From the final prospectus (Form 424B4) and the first day of trading
SPAC offering
- Type
- SPAC (blank check) IPO of units
- Final prospectus filed
- Dec 21, 2020
- Offer price
- $10.00
- Securities offered
- 3,300,000
- Gross proceeds
- $33.00M
- Exchange
- Nasdaq
- First trading day
- Feb 8, 2021
- First-day close
- $10.52+5.2%
- Lock-up ends (est.)
- Aug 7, 2021
“Each unit has an offering price of $10.00 and consists of one share of our Class A common stock and one-third of one redeemable warrant.”
Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.
Employees
Headcount reported in annual reports
“As of December 31, 2025, we had approximately 102 full-time employees,”
Corporate history
Events identified from SEC filings
See a number that looks wrong?